Effects of a bicarbonate-alkaline mineral water on digestive motility in experimental models of functional and inflammatory gastrointestinal disorders.
This study investigates the effects of Uliveto, a bicarbonate-alkaline mineral water, in experimental models of diarrhea, constipation and colitis. Rats were allowed to drink Uliveto or oligomineral water (control) for 30 days. Diarrhea and constipation were evoked by 16,16-dimethyl-prostaglandin E(2) (dmPGE(2)) or loperamide, respectively. Colitis was induced by 2,4-dinitrobenzenesulfonic acid (DNBS) or acetic acid. Gastric emptying, small-intestinal and colonic transit were evaluated. dmPGE(2)-induced diarrhea reduced gastric emptying and increased small-intestinal and colonic transit. In this setting, Uliveto water enhanced gastric emptying, and this effect was prevented by L-365,260 (gastrin receptor antagonist). Loperamide-induced constipation reduced gastric emptying, small-intestinal and colonic transit, and these effects were prevented by Uliveto water. L-365,260 counteracted the effects of Uliveto on gastric emptying, while alosetron (serotonin 5-HT(3) receptor antagonist) blunted the effect of Uliveto on colonic transit. Gastric emptying, small-intestinal and colonic transit were reduced in DNBS-induced colitis, and Uliveto water enhanced gastric emptying and normalized small-intestinal and colonic transit. Gastric emptying, small-intestinal and colonic transit were also reduced in acetic acid-induced colitis, and Uliveto increased both gastric emptying and small-intestinal transit. In conclusion, Uliveto water exerts beneficial effects on gastrointestinal motility in the presence of bowel motor dysfunctions. The effects of Uliveto water on gastric emptying depend on gastrin-mediated mechanisms, whereas the activation of serotonergic pathways accounts for the modulation of colonic functions.
Fornai
M
M
Interdepartmental Centre for Research in Clinical Pharmacology and Experimental Therapeutics, University of Pisa, Pisa, Italy.
Colucci
R
R
Antonioli
L
L
Ghisu
N
N
Tuccori
M
M
Gori
G
G
Blandizzi
C
C
Del Tacca
M
M
D000818:Animals; D001570:Benzodiazepinones / Q000494:pharmacology; D001639:Bicarbonates / Q000008:administration & dosage / Q000494:pharmacology*; D003092:Colitis / Q000188:drug therapy; D003248:Constipation / Q000188:drug therapy; D003967:Diarrhea / Q000188:drug therapy; D004195:Disease Models, Animal; D005746:Gastric Emptying / Q000187:drug effects; D005755:Gastrins / Q000378:metabolism; D005769:Gastrointestinal Motility / Q000187:drug effects*; D006863:Hydrogen-Ion Concentration; D008297:Male; D008900:Mineral Waters / Q000008:administration & dosage / Q000627:therapeutic use*; D010671:Phenylurea Compounds / Q000494:pharmacology; D051381:Rats; D017208:Rats, Wistar; D044406:Receptors, Serotonin, 5-HT3 / Q000187:drug effects / Q000378:metabolism
D001570:Benzodiazepinones; D001639:Bicarbonates; D005755:Gastrins; D008900:Mineral Waters; D010671:Phenylurea Compounds; D044406:Receptors, Serotonin, 5-HT3; C058121:L 365260